Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 6.61 USD -4.48% Market Closed
Market Cap: 1.3B USD

Relative Value

There is not enough data to reliably calculate the relative value of SVRA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SVRA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-8.1
Industry
23.7
Forward
-12.5
vs History
vs Industry
Median 3Y
-12
Median 5Y
-8.9
Industry
22
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-8.5
Industry
23.8
vs History
0
vs Industry
36
Median 3Y
5.3
Median 5Y
3.7
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-9
Median 5Y
-5.4
Industry
6.4
Forward
-32.1
vs History
vs Industry
Median 3Y
-9
Median 5Y
-5.4
Industry
7
Forward
-10.2
vs History
vs Industry
Median 3Y
-10.8
Median 5Y
-6
Industry
8.3
vs History
vs Industry
Median 3Y
-10.8
Median 5Y
-6
Industry
6.5
vs History
0
vs Industry
12
Median 3Y
46.2
Median 5Y
28.5
Industry
5.7

Multiples Across Competitors

SVRA Competitors Multiples
Savara Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Savara Inc
NASDAQ:SVRA
1.3B USD 0 -11.6 -10.3 -10.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
402B USD 6.7 171.2 16.6 23.5
US
Amgen Inc
NASDAQ:AMGN
175B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
148.8B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.8B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
86B AUD 3.7 19 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 184.3 155.5 188.6
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.9 58.4 60
P/S Multiple
Revenue Growth P/S to Growth
US
Savara Inc
NASDAQ:SVRA
Average P/S: 3 374 064.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 738 486.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 088.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.3
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Savara Inc
NASDAQ:SVRA
Average P/E: 187.6
Negative Multiple: -11.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
9%
1.9
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 184.3
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Savara Inc
NASDAQ:SVRA
Average EV/EBITDA: 39.1
Negative Multiple: -10.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.4
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Savara Inc
NASDAQ:SVRA
Average EV/EBIT: 45.2
Negative Multiple: -10.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.6
N/A N/A
NL
argenx SE
XBRU:ARGX
60
N/A N/A